{"id":50679,"date":"2022-11-09T22:02:07","date_gmt":"2022-11-09T21:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/"},"modified":"2022-11-09T22:02:07","modified_gmt":"2022-11-09T21:02:07","slug":"kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kezarlifesciences.com%2F&amp;esheet=52965399&amp;newsitemid=20221109005819&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=146c224660ccc452fbec32a5f772a708\" rel=\"nofollow noopener\" shape=\"rect\">Kezar Life Sciences, Inc<\/a>. (Nasdaq: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DA_RIahtrUVTv8Q2QWR0HpAmRn2O356LUbz7rJKjA_NLAm-SZ1-4boOMh-vd7Ykoph8mVDvzxN0EOF3tbEhfpYt8Ge4Zb7a6CzG8-dXn2c3KgkxQG6HIe6QyAxE1CHMcI&amp;esheet=52965399&amp;newsitemid=20221109005819&amp;lan=en-US&amp;anchor=KZR&amp;index=2&amp;md5=dd81434aeb97606920887ede14f4d840\" rel=\"nofollow noopener\" shape=\"rect\">KZR<\/a>), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/5\/Kezar_Life_Sciences_logo_July_2022.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg\"><\/a><\/p>\n<p>\n<b>Presentation Details:<\/b>\n<\/p>\n<p>\n<b>Event:<\/b> Jefferies London Healthcare Conference<br \/>\n<br \/><b>Location:<\/b> London, UK<br \/>\n<br \/><b>Date\/Time:<\/b> Wednesday, November 16, 2022, at 8:35 AM GMT<br \/>\n<br \/><b>Presenter:<\/b> Noreen Roth Henig, M.D., Chief Medical Officer<br \/>\n<br \/><b>Format:<\/b> Fireside Chat\n<\/p>\n<p>\n<b>Event:<\/b> Evercore ISI 5<sup>th<\/sup> Annual HealthCONx Conference<br \/>\n<br \/><b>Location:<\/b> Boston, MA<br \/>\n<br \/><b>Date\/Time:<\/b> Wednesday, November 30, 2022, at 12:10 PM ET<br \/>\n<br \/><b>Presenters:<\/b> John Fowler, Co-Founder, Chief Executive Officer<br \/>\n<br \/><b>Format:<\/b> Fireside Chat\n<\/p>\n<p>\nWebcasts from the presentations will be available on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.kezarlifesciences.com&amp;esheet=52965399&amp;newsitemid=20221109005819&amp;lan=en-US&amp;anchor=www.kezarlifesciences.com&amp;index=3&amp;md5=8a7e6e27adb6cb21bc5ae23592fdb338\" rel=\"nofollow noopener\" shape=\"rect\">www.kezarlifesciences.com<\/a>. Following the events, archived webcasts will be available on the Kezar website for 90 days.\n<\/p>\n<p>\n<b>About Kezar Life Sciences<\/b>\n<\/p>\n<p>\nKezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company\u2019s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.kezarlifesciences.com%2F&amp;esheet=52965399&amp;newsitemid=20221109005819&amp;lan=en-US&amp;anchor=www.kezarlifesciences.com&amp;index=4&amp;md5=0536c9c1f2ee7bf15530eb333cac9a9e\" rel=\"nofollow noopener\" shape=\"rect\">www.kezarlifesciences.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Contact:<\/b><br \/>Gitanjali Jain<br \/>\n<br \/>Vice President, Investor Relations and External Affairs<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#103;j&#x61;&#105;n&#x40;&#107;e&#x7a;&#97;r&#x62;&#105;o&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x67;&#x6a;&#x61;&#105;&#110;&#64;k&#x65;&#x7a;&#x61;&#x72;&#98;&#105;o&#46;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Julia Deutsch<br \/>\n<br \/>Solebury Strategic Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;j&#x64;&#x65;&#117;&#x74;s&#x63;&#x68;&#64;&#x73;o&#x6c;&#x65;&#98;&#x75;r&#x79;&#x73;&#116;&#x72;a&#x74;&#x2e;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x6a;&#100;&#101;&#x75;&#x74;&#115;&#99;&#x68;&#x40;&#115;&#111;&#x6c;&#x65;&#98;&#117;&#x72;&#x79;&#115;&#116;&#x72;&#x61;&#116;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date\/Time: Wednesday, November 16, 2022, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50679","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date\/Time: Wednesday, November 16, 2022, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T21:02:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2022-11-09T21:02:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":298,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005819\\\/en\\\/1564741\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005819\\\/en\\\/1564741\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"datePublished\":\"2022-11-09T21:02:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005819\\\/en\\\/1564741\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005819\\\/en\\\/1564741\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November. Presentation Details: Event: Jefferies London Healthcare Conference Location: London, UK Date\/Time: Wednesday, November 16, 2022, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-09T21:02:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences","datePublished":"2022-11-09T21:02:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":298,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/","name":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","datePublished":"2022-11-09T21:02:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221109005819\/en\/1564741\/21\/Kezar_Life_Sciences_logo_July_2022.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50679"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50679\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}